References
- Hook EB, Cross PK, Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA 1983;249:2034–2038.
- Snijders RJ, Sebire NJ, Nicolaides KH. Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther 1995;10:356–367.
- Marttala J, Yliniemi O, Gissler M, Nieminen P, Ryynanen M. Prevalence of Down’s syndrome in a pregnant population in Finland. Acta Obstet Gynecol Scand 2010;89:715–717.
- Marttala J, Peuhkurinen S, Ranta JK, Laitinen P, Kokkonen HL, Honkasalo T, Ryynanen M. Screening and outcome of chromosomal abnormalities other than trisomy 21 in Northern Finland. Acta Obstet Gynecol Scand 2010; submitted.
- Shaw J. Trisomy 18: a case study. Neonatal Netw 2008;27:33–41.
- de Grouchy J, Turtleau C. Clinical atlas of human chromosomes. New York: John Wiley & Sons;1984.
- Wewer UM, Albrechtsen R, Engvall E. ADAM12: The long and the short of it. In: Hooper NM, Lendeckel U, Eds. The ADAM family of proteases. 4th ed. London (UK): Kluwer Academic/Springer; 2005.
- Laigaard J, Sørensen T, Fröhlich C, Pedersen BN, Christiansen M, Schiøtt K, Uldbjerg N, et al. ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 2003;23:1086–1091.
- Laigaard J, Christiansen M, Fröhlich C, Pedersen BN, Ottesen B, Wewer UM. The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18. Prenat Diagn 2005;25:45–46.
- Laigaard J, Sørensen T, Placing S, Holck P, Fröhlich C, Wøjdemann KR, Sundberg K, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005;106:144–149.
- Spencer K, Cowans NJ. ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy. J Matern Fetal Neonatal Med 2007;20:645–650.
- Spencer K, Cowans NJ, Stamatopoulou A. Maternal serum ADAM12s as a marker of rare aneuploidies in the first or second trimester of pregnancy. Prenat Diagn 2007;27:1233–1237.
- Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down’s syndrome associated pregnancy. Ann Clin Biochem 1990;27 (Pt 5):452–458.
- Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down’s syndrome. Prenat Diagn 1997;17:821–829.
- Cuckle HS, van Lith JM. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999;19:505–512.
- Tsukerman GL, Gusina NB, Cuckle HS. Maternal serum screening for Down syndrome in the first trimester: experience from Belarus. Prenat Diagn 1999;19:499–504.
- Valinen Y, Laitinen P, Ranta J, Ignatius J, Jarvela I, Ryynänen M. Effect of a new marker, ADAM12, on Down risk figures in first trimester screening. J Matern Fetal Neonatal Med 2009;22:602–607.
- Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH. Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks. Am J Obstet Gynecol 2009;200:508.e1–508.e6.
- Valinen Y, Peuhkurinen S, Järvelä IY, Laitinen P, Ryynanen M. Maternal serum ADAM12 levels correlate with PAPP-A levels during the first trimester. Gynecol Obstet Invest 2010;70:60–63.
- Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, Pedersen BN, Wewer UM. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 2006;26:973–979.